Angiotensin (1-7) (Synonyms: Asp-Arg-Val-Tyr-Ile-His-Pro ) |
| Catalog No.GP10077 |
Angiotensin (1-7), a heptapeptide found in the heart and kidney, inhibits angiotensin-converting enzyme (ACE) in plasma and atrial tissue with an IC50 of 3.0 and 4.0μM, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 51833-78-4
Sample solution is provided at 25 µL, 10mM.
Angiotensin (1-7), a heptapeptide found in the heart and kidney, inhibits angiotensin-converting enzyme (ACE) in plasma and atrial tissue with an IC50 of 3.0 and 4.0μM, respectively[1]. Angiotensin (1-7) has been identified as regulating blood pressure, cardiac function and smooth muscle and myocardial cell growth as well as renal function regulation[2]. Angiotensin (1-7) has been extensively studied for modulation of vascular function in various cellular and animal models[3].
In vitro, Angiotensin (1-7) treatment (1nM; 48h) effectively reduced the proliferation of DU-145 prostate cancer cells and induced a significant reduction in the expression of MKI67[4]. Treatment of mouse podocytes with Angiotensin (1-7) at 10μM for 24 hours reversed high glucose-induced reduction of podocyte viability, increase of podocyte apoptosis, reduction of nephrin, podocin, WT-1 and MasR protein expression, and up-regulation of AT1R expression[5]. Angiotensin (1-7) treatment (1.7μM; 18 hours) effectively reduced tube formation in human umbilical vein endothelial cells[6].
In vivo, Angiotensin (1-7) treatment via daily intraperitoneal injection at 2mg/kg ameliorated sepsis-induced cardiomyopathy in mice by reducing inflammatory response and mitochondrial damage through NF-κB and MAPK pathways[7]. A single dose of 45μg/kg Angiotensin (1-7) administration via gavage promoted the resolution of lipopolysaccharide-induced pleurisy in mice by reducing neutrophil numbers and M1 inflammatory macrophage frequency after 24h treatment[8].
References:
[1] Roks A J M, Van Geel P P, Pinto Y M, et al. Angiotensin-(1–7) is a modulator of the human renin-angiotensin system[J]. Hypertension, 1999, 34(2): 296-301.
[2] Padda R S, Shi Y, Lo C S, et al. Angiotensin-(1-7): a novel peptide to treat hypertension and nephropathy in diabetes?[J]. Journal of diabetes & metabolism, 2015, 6(10): 10.4172/2155-6156.1000615.
[3] Durand M J, Zinkevich N S, Riedel M, et al. Vascular actions of angiotensin 1–7 in the human microcirculation: novel role for telomerase[J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36(6): 1254-1262.
[4] Domińska K, Okła P, Kowalska K, et al. Angiotensin 1–7 modulates molecular and cellular processes central to the pathogenesis of prostate cancer[J]. Scientific Reports, 2018, 8(1): 15772.
[5] Lu J, Chen G, Shen G, et al. Ang-(1-7) attenuates podocyte injury induced by high glucose in vitro[J]. Archives of Endocrinology and Metabolism, 2023, 67: e000643.
[6] Anton L, Merrill D C, Neves L A A, et al. Angiotensin-(1–7) inhibits in vitro endothelial cell tube formation in human umbilical vein endothelial cells through the AT1–7 receptor[J]. Endocrine, 2007, 32(2): 212-218.
[7] Chen X S, Cui J R, Meng X L, et al. Angiotensin-(1–7) ameliorates sepsis-induced cardiomyopathy by alleviating inflammatory response and mitochondrial damage through the NF-κB and MAPK pathways[J]. Journal of Translational Medicine, 2023, 21(1): 2.
[8] de Carvalho Santuchi M, Dutra M F, Vago J P, et al. Angiotensin‐(1‐7) and alamandine promote anti‐inflammatory response in macrophages in vitro and in vivo[J]. Mediators of Inflammation, 2019, 2019(1): 2401081.
| Cell experiment [1]: | |
Cell lines | DU-145 cell |
Preparation Method | The DU-145 cells underwent two or more passages following recovery from liquid nitrogen storage and cultured in DMEM medium under humidity-controlled conditions at 37 °C with 5% CO2. The standard supplements were also used, including 10% heat-inactivated Fetal Bovine Serum (FBS), 1mM Sodium Pyruvate, 10mM HEPES buffer, and antibiotics (penicillin 50U/ml; streptomycin 50mg/ml; neomycin 100mg/ml). Angiotensin (1-7) was added to the cell culture medium at concentration 1nM. Four hours before the end of incubation period (48 hours) a MTT working solution at final concentration of 0.5mg/ml was added to each well. Formazan crystals formed by viable cells were dissolved in 10% sodium deodecyl sulfate (SDS) solution in 0.01M HCl. The absorbance was measured at 570nm using a microplate reader. Cell viability (% of control) was calculated in relation to untreated cells. The changes in cell proliferation after Angiotensin (1-7) treatment (1nM; 48 hours) were determined using a BrdU Cell Proliferation Assay. |
Reaction Conditions | 1nM; 48h |
Applications | Angiotensin (1-7) significantly inhibited the viability and proliferation of DU-145 cells. |
| Animal experiment [2]: | |
Animal models | Male Wistar rats |
Preparation Method | Male Wistar rats (10 weeks old, 200-250g) were given free access to standard rat chow and water during the experiment. Following a 5-day period of acclimatization, 120 rats were randomly divided into two groups: control group (n=15), receiving an intraperitoneal injection of normal saline, and diabetic group (n=105), receiving intraperitoneal injection of 65mg/kg streptozotocin (STZ) dissolved in sodium citrate buffer (pH 4.5). All diabetic rats received an intraperitoneal injection of insulin (2-3U) every 3 days to maintain blood glucose levels between 16.7 and 25mM to avoid death induced by excessively high blood glucose level. Twelve weeks after STZ injection, the diabetic rats were randomly divided into 7 treatment groups (n=15 per group): no-treatment group and Angiotensin (1-7) group that received subcutaneous injection of 800ng/kg/min of Angiotensin (1-7) by an embedded mini-osmotic pump. After treatment for 4 weeks, all rats were killed. Plasma and kidney samples from rats were collected for cytokine and histological analysis. |
Dosage form | 800ng/kg/min for 4 weeks; s.c. |
Applications | Angiotensin (1-7) treatment ameliorated streptozotocin-induced renal injury, attenuated glomerulosclerosis, and reduced the expression of TGF-β1, VEGF and NOX4. |
References: | |
| Cas No. | 51833-78-4 | SDF | |
| Synonyms | Asp-Arg-Val-Tyr-Ile-His-Pro | ||
| Chemical Name | Angiotensin (1-7) | ||
| Canonical SMILES | CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N | ||
| Formula | C41H62N12O11 | M.Wt | 899 |
| Solubility | ≥89.9mg/mL in DMSO | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1123 mL | 5.5617 mL | 11.1235 mL |
| 5 mM | 222.5 μL | 1.1123 mL | 2.2247 mL |
| 10 mM | 111.2 μL | 556.2 μL | 1.1123 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *